FcγR and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

FcγR and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer

Published:2014-05-15 Issue:5 Volume:18 Page:541-548
ISSN:1177-1062
Container-title:Molecular Diagnosis & Therapy
language:en
Short-container-title:Mol Diagn Ther

Author:

Inoue Yuka,Hazama Shoichi,Iwamoto Shigeyoshi,Miyake Yasuhiro,Matsuda Chu,Tsunedomi Ryouichi,Okayama Naoko,Hinoda Yuji,Yamasaki Takahiro,Suehiro Yutaka,Yoshino Shigefumi,Sakamoto Junichi,Mishima Hideyuki,Oka Masaaki

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40291-014-0103-6.pdf

Reference33 articles.

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41. doi: 10.3322/caac.21149 .

2. Tsukuma H, Ajiki W, Ioka A, Oshima A. Survival of cancer patients diagnosed between 1993 and 1996: a collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol. 2006;36(9):602–7. doi: 10.1093/jjco/hyl068 .

3. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103–14. doi: 10.1016/s0140-6736(11)60613-2 .

4. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755–62. doi: 10.1200/jco.2011.38.0915 .

5. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–5. doi: 10.1158/0008-5472.can-06-0191 .

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on the expression of IgG in prostate cancer and its effect on prostate cancer;2023-12-19

2. Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC;Pharmaceutics;2022-11-15

3. Understanding Inter-Individual Variability in Monoclonal Antibody Disposition;Antibodies;2019-12-04

4. Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin‑based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials;Oncology Letters;2019-08-29

5. Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer;Advances in the Molecular Understanding of Colorectal Cancer;2019-02-06